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entire patient population was 71% (404 of 565). Out of 35 patients that did not achieve SVR after DAA
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Summary
BACKGROUND: The introduction of direct acting antivi-
rals (DAAs) for the therapy of chronic hepatitis C (CHC)
has revolutionised treatment and marks a paradigm shift
in the approach to this disease, rendering interferon-based
therapies obsolete.
AIMS OF THE STUDY: We retrospectively and prospec-
tively evaluated treatment results after the introduction of
DAA in Switzerland in a cohort of patients with CHC.
METHODS: We examined 565 patients who received DAA
treatment for CHC between November 2013 and June
2016 with regard to HCV genotype, fibrosis stadium, treat-
ment and outcome. In addition, outcome of re-treatment
and resistance-associated substitutions (RAS) in patients
that did not achieve sustained virological response (SVR)
were evaluated. The majority of patients participate in the
Swiss Hepatitis C Cohort Study. Data were evaluated in an
intention-to-treat and a modified intention-to-treat analy-
sis.
RESULTS: Overall SVR rate for all patients was 94% (530
of 565, 95% CI 92–96%). Of 350 patients with HCV geno-
type 1 CHC, 335 achieved SVR, resulting in an SVR rate
of 96% (335 of 350, 95% CI 94–98%). Patients with HCV
genotype 2 achieved SVR in 94% (48 of 51, 95% CI
87–100%). Patients with HCV genotype 3 showed SVR
of 92% (98 of 107, 95% CI 87–97%). In patients with
HCV genotype 4, the SVR rate was substantially lower at
85% (49 of 57, 95% CI 76–94%). The rate of advanced
liver fibrosis (Metavir F3/F4) assessed by means of liver
biopsy or Fibroscan® in the entire patient population was
71% (404 of 565). Out of 35 patients that did not achieve
SVR after DAA treatment, 32 had a relapse and 3 patients
showed viral breakthrough. In 17 of 35 cases (49%) pa-
tients were treatment naïve and 21 of 35 patients (60%)
were cirrhotic. RAS genotyping of HCV was performed in
14 patients. Nine of these 14 patients (60%) carried muta-
tions in the NS5A region of the virus genome. Twenty-sev-
en percent of patients who experienced treatment failure
were not treated with recommended regimens as a result
of drug availability and reimbursement limitations.
CONCLUSION: In Switzerland, novel DAA treatments for
CHC reflect the positive results from registration trials.
Genotypes 2 and 4 remained more difficult to treat be-
tween 2014 and 2016. Patients who experienced a re-
lapse after DAA treatment in Switzerland predominantly
showed mutations in the NS5A region of the virus
genome. DAA treatment limitations in Switzerland did pre-
vent optimal treatment regimens in some patients.
Key words: chronic Hepatitis C, direct acting antivirals,
sustained virological response
Introduction
Interferon-free direct antiviral agents (DAAs) for the treat-
ment of chronic hepatitis C (CHC) became available in
Switzerland in December 2013. In large registration stud-
ies, DAA treatment resulted in sustained virological re-
sponse (SVR) rates of more than 90% in many patient pop-
ulations with minimal side effects [1–3]. Based on these
registration studies, recommendations of the major nation-
al and international societies quickly adopted the novel
treatment regimens for most patients, rendering previous
pegylated-interferon (PEG-IFN)-based regimens obsolete
(summarised in the EASL and AASLD guidelines on the
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EASL European Association for the Study of the Liver
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treatment of chronic hepatitis C virus [HCV] infection) [4,
5].
With the widespread use of DAA in diverse clinical set-
tings and patient populations, initial registration study re-
sults have been challenged by so-called “real life” data
that, in several cases, were clearly inferior to the SVR rates
expected on the basis of phase III trials [6, 7]. These data
remain controversial, with other studies finding SVR rates
similar to registration trials (e.g., treatment in age >65 [8]
or human immunodeficiency virus [HIV] co-infected [9]).
Given the significant cost and burden to healthcare systems
due to the high large number of CHC patients and the high
costs of DAA, the success rate and performance of these
novel drugs in a clinical situation outside of registration
studies is of major interest. Furthermore, it allows for the
evaluation of recommended treatment regimens as well as
critical evaluation of current local access to medication and
reimbursement restrictions.
The aim of this study was to assess treatment regimens and
success rates of patients with CHC in Switzerland, and to
review access and reimbursement limitations with regards
to treatment outcome.
Materials and methods
Study design
This was an observational study assessing treatment regi-
mens and treatment outcome of a patient cohort suffering
from CHC. Reporting of data follows the STROBE State-
ment (Strengthening the Reporting of Observational stud-
ies in Epidemiology) for observational epidemiological
studies [10].
Setting
The present study was conducted at three Swiss tertiary
care centres (University Hospital Zurich, Kantonsspital St
Gallen, Epatocentro Ticino, Lugano). Data collection was
performed retrospectively as well as prospectively. Data
were analysed per intention-to-treat (ITT) analysis, and per
modified ITT analysis with respect to HCV genotype, reg-
imen of DAA therapy, treatment outcome as well as re-
treatment in patients who did not achieve SVR after the
first course of DAA. Patients were recruited between No-
vember 2013 and June 2016. Most patients are participants
in the Swiss Hepatitis C Cohort Study [11].
Participants
Five hundred and eighty-five patients with CHC under-
going DAA treatment between November 2013 and June
2016 were evaluated. DAA treatment regimens were cho-
sen according to current recommendations of the European
Association for the study of the Liver (EASL), Swiss ex-
pert opinion statement and/or treatment according to avail-
ability, and reimbursement limitations of the Swiss health
authorities.
Inclusion criteria were (1) age older than 18 years (2), a
documented HCV infection (3), a DAA-based therapy for
CHC (4), available data on HCV treatment including lab-
oratory data and documented HCV viral load (HCV RNA
by PCR [COBAS 4800; Roche Diagnostics, Rotkreuz,
Schweiz]), and (5) patient informed consent. Patients not
meeting these criteria were not included in the study (see
fig. 1). Concomitant liver diseases and co-infections were
recorded if available.
Variables
Patients were divided into five groups according to HCV
genotype and subtype (1a, 1b, 2–4). Patients with HCV
genotype 1 were divided into the subgroups 1a and 1b,
since the treatment regimen differs for the two subtypes.
In contrast, the other HCV genotypes (2, 3 and 4) were
treated with a genotype-specific regimen regardless of sub-
type. Because of the scarcity of these genotypes in Switzer-
land, no patients with HCV genotype 5 or 6 infection were
included in the study. Successful treatment was defined
as negative HCV-PCR 12 weeks after end of treatment
(SVR12). Treatment failure was defined as again positive
HCV-PCR during antiviral therapy (breakthrough) or after
end of treatment (relapse).
Data sources/measurement
HCV genotyping was performed by a line probe assay
(Versant HCV Genotype 2.0 Assay, Siemens/Realtime
HCV Genotype II, Abbott) and assessment of viral load
was performed by a PCR-based test (COBAS 4800; Roche
Diagnostics, Rotkreuz, Schweiz). SVR was defined as un-
detectable HCV RNA by PCR at week 12 after treatment.
The lower limit of detection of the HCV-PCR assay was
10 IU/ml at University Hospital Zurich and 15 IU/ml at
Kantosspital St Gallen and Epatocentro Ticino. Liver fi-
brosis was assessed histologically by means of liver biopsy
or non-invasively by transient elastography (Fibroscan®).
Results were graded according to Metavir F stages with
transient elastography values of >9.5 kPa corresponding
to Metavir F3 while transient elastography values >12.5
equalling Metavir F4 [12]. If both biopsy and transient
elastography results were available, transient elastography
values were only used for analysis if more recent than
biopsy.
Bias
To control for a selection bias, the study had defined inclu-
sion and exclusion criteria, which reflects the Swiss CHC
population undergoing antiviral treatment.
Study size
All patients with CHC undergoing DAA treatment be-
tween November 2013 and June 2016 from three tertiary
Swiss hepatology centres were screened for study partici-
pation.
Statistical methods
Statistical analysis was performed using SPSS 22.0 (IBM
Corp, Armonk, NY USA). Graphs were generated using
PowerPoint (Version 14.6.9, Microsoft PowerPoint Mac
OS X 2011). Patients lost to follow-up were excluded be-
fore performing statistical evaluations (see fig. 1).
Ethics statement
The study protocol was designed according to the ethical
guidelines of the 1975 Helsinki Declaration. The ethics
committee of the Canton of Zurich (BASEC 2016-00341)
and the ethics committees of the participating centres
(BASEC 2016-00171) approved the present study. Written
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informed consent of all patients was obtained. For the sta-
tistical analysis all clinical data were anonymised.
Results
Patient and treatment characteristics
A total of 584 patients from three centres undergoing DAA
treatment for CHC were evaluated. Eighteen patients did
not meet inclusion criteria and were therefore excluded
from further analysis (fig. 1). The 565 remaining patients
that underwent DAA treatment with a minimal post-treat-
ment follow-up of 12 weeks were included and a modified
ITT analysis was performed. Characteristics of the cohort
are shown in table 1. Seventy-one percent (403 of 565,
71.3%) of patients had Metavir F3 or F4 fibrosis as deter-
mined by biopsy or transient elastography. Two hundred
and fifty-seven patients in our study suffered from liver
cirrhosis (liver fibrosis stage F4). Among those cirrhotic
patients there were 197 patients with Child-Pugh Class A
(197 of 257, 77%) and 18 patients with Child-Pugh Class B
(18 of 257, 7%). There was no cirrhotic patient with Child-
Pugh Class C. Five-hundred-twelve patients received an
interferon-free DAA combination ± ribavirin (512 of 565,
90.6%) and 53 patients a combination of PEG-IFN, rib-
avirin and sofosbuvir (53 of 565, 9.4%). Mean treatment
duration for all patients was 15 weeks. Overall SVR rate
was 94% (530 of 565, 93.8%, 95% CI 92–96%) for all pa-
tients treated (fig. 2). Of the patients without cirrhosis (fi-
brosis stage F1–F3), 95% reached SVR (286 of 300, 95%
CI 93–97%). SVR rate in patients with liver cirrhosis (fi-
brosis stage F4) was lower (236 of 259, 92%, 95% CI
88–94%). Cirrhotic patients with Child-Pugh Class A
reached SVR in 91% (179 of 197, 95% CI 87–95%) and
cirrhotic patients with Child-Pugh Class B reached SVR
in 83% (15 of 18, 95% CI 65–100%]) of cases. Fifty-five
percent of all patients were treatment naïve (310 of 565,
54.9%), 46 patients had a concomitant HIV infection (46
of 565, 8.1%), 6 patients had a hepatitis B virus (HBV) in-
fection (6 of 565, 1%) and 2 patients suffered from HIV
and HBV co-infection (2 of 565, 0.4%). There was one
case of each of the following: primary biliary cholangitis,
primary sclerosing cholangitis, haemochromatosis, au-
toimmune hepatitis and Wilson’s disease (1 of 565, 0.2%).
Reasons for exclusion from the final analysis were liver
transplantation during the course of therapy (5 of 584,
Figure 1: Flow chart of patient recruitment.
0.9%), change in HCV treatment (2 of 584, 0.3%) and
missing data (2 of 584, 0.3%). One patient stopped the
treatment because of reasons other than adverse events (1
of 584, 0.2%). There were no SVR data for five patients at
the time of analysis (5 of 584, 0.9%) and four patients (4
of 584, 0.7%) were lost to follow-up.
Reporting SVR results by ITT analysis, overall SVR rates
were (530 of 575, 92%, 95% CI 90–94%). In this analysis
the following 10 patients are included: one patient who
stopped the treatment (1 of 10, 10%), five patients who had
no SVR value (5 of 10, 50%) and four patients who were
lost to follow-up (4 of 10, 40%). The following results on
treatment outcome are from a modified ITT from which
the previously mentioned 10 patients were excluded.
Table 1: Patients' baseline characteristics (n = 565).
Age (years), median (range) 56 (21–86)
Male sex, n (%) 356 (63.0)
Body mass index (kg/m2), mean (range)] 25.34 (16.0–41.9)
HCV genotype, n (%)
1 350 (62.0)
2 51 (9.0)
3 107 (18.9)
4 57 (10.1)
HCV RNA (log10 IU/ml), median (range) 6.08 (1.5–7.5)
Liver stiﬀness (kPa), median (range) 12.10 (3.1–75.0)
Treatment history, n (%)
Treatment naive 310 (54.9)
Relapse 128 (22.7)
Breakthrough 19 (3.4)
Non-response 85 (15.0)
Premature discontinuation 21 (3.7)
Other 2 (0.4)
Co-infections, n (%)
HIV 46 (8.1)
HBV 6 (1.1)
HIV + HBV 2 (0.4)
No co-infection 511 (90.4)
Metavir, n (%)
F1 (≤7.5) 78 (13.8)
F2 (7.6–9.5) 76 (13.5)
F3 (9.6–12.5) 146 (25.8)
F4 (≥12.6) 257 (45.5)
No data 8 (1.4)
HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immun-
odeficiency virus
Figure 2: Overall SVR rate and SVR rates for individual HCV
genotypes. Eight patients with not further specified genotype 1 are
not included in this figure.
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Treatment outcome by genotype
Patients with HCV genotype 1a (n = 167; supplementary
fig. S1a in appendix 1) had an overall SVR rate of 95%
(158 of 167, 95% CI 92–98%). Seventy-one percent (118
of 167) of patients with genotype 1a had advanced fibrosis
(Metavir F3/4), and 94% (111 of 118, 95% CI 90–98%)
of these achieved SVR. Genotype 1a patients received so-
fosbuvir-containing treatment in 81% (136 of 167), while
19% (31 of 167) were treated with a combination of ri-
tonavir-boosted paritaprevir with ombitasvir and dasabuvir
with (n = 26) or without (n = 5) ribavirin for 12 weeks.
In the patient group that received paritaprevir/ritonavir/
ombitasvir and dasabuvir, 3 out of 31 patients (9.6%) did
not reach SVR. Sofosbuvir was most frequently combined
with ledipasvir (95 of 136 sofosbuvir treatments, 70%),
daclatasvir (13 of 135 sofosbuvir treatments, 9.5%) and
simeprevir (11 of 136 sofosbuvir treatments, 8%). Seven-
teen patients were treated with sofosbuvir and ribavirin on-
ly (17 of 136 sofosbuvir treatments, 12.5%). Overall SVR
rate of sofosbuvir-containing regimens was 95% (130 of
136, 95% CI 91–99%). Most relapses (5 out of 95, 5%)
were seen in patients receiving a combination of sofosbu-
vir/ledipasvir with or without ribavirin for 8 weeks (one re-
lapse without ribavirin; see fig. 3), 12 weeks (three relaps-
es) or 24 weeks (one relapse). All patients who received
sofosbuvir/ribavirin for 12 or 24 weeks (n = 17) or sofos-
buvir/daclatasvir with or without ribavirin for 24 weeks (n
= 13) reached SVR, while there was one relapse among the
11 patients treated with sofosbuvir/simeprevir/ribavirin for
12 weeks (1 of 11, 9%). Of all relapses, most patients were
cirrhotic and/or had prior treatment failure (7 of 9, 78%).
Genotype 1b patients (fig. S1b) were treated with sofos-
buvir-containing regimens in 69% (120 of 175). Most of
these patients had a combination of sofosbuvir with ledi-
pasvir with or without ribavirin (89 of 120, 74%). Twelve
patients had a combination of sofosbuvir plus ribavirin
(12 of 120, 10%), 8 patients received sofosbuvir plus da-
clatasvir with or without ribavirin (8 of 120, 7%) and
11 patients were treated with sofosbuvir plus simeprevir
with or without ribavirin (11 of 120, 9%). Fifty-four pa-
tients were treated with paritaprevir/ritonavir/ombitasvir
and dasabuvir with or without ribavirin in 31% of cases (54
of 175). One patient received a combination of daclatasvir/
simeprevir for 12 weeks but did have a viral breakthrough.
All other genotype 1b relapses occurred in patients treated
with sofosbuvir containing regimens (5 of 120; 4%), while
all patients that received paritaprevir/ritonavir/ombitasvir
and dasabuvir with or without ribavirin for 12 weeks or 24
weeks reached SVR.
For genotype 2 HCV patients (fig. S2), the only DAA reg-
imen available in Switzerland until 2016 was sofosbuvir/
ribavirin for 12, 16, 20 or 24 weeks. Thirty-six were treat-
ed for 12 weeks, 5 for 16 weeks, 7 for 20 weeks and 3 for
24 weeks. Three out of 51 patients (6%) did not achieve
SVR. One patient was a treatment-naïve cirrhotic and re-
ceived sofosbuvir/ribavirin for 12 weeks, the other two pa-
tients were treatment-experienced. One of them was cir-
rhotic and was treated for 20 weeks.
Similarly, all 107 genotype 3 patients (fig. S3) received a
sofosbuvir-based treatment. For most patients sofosbuvir,
was combined with daclatasvir with or without ribavirin
for 12 or 24 weeks (52 of 107; 49%) or sofosbuvir was giv-
en with ribavirin for 12, 24 or 36 weeks (50 of 107; 47%).
Relapse rate in the sofosbuvir/ribavirin group was 6% (3
of 50, 6%), with one relapse after 12 weeks and two after
24 weeks of therapy. Four patients were treated with so-
fosbuvir/ledipasvir and one of these (25%) experienced a
relapse. One patient received a combination with sofosbu-
vir and simeprevir without ribavirin for 12 weeks and did
achieve SVR.
The majority of genotype 4 patients (fig. S4) also received
sofosbuvir as part of the DAA treatment regimen (52 out
of 57; 91%). The majority received sofosbuvir in com-
bination with ribavirin (22 out of 52, 42%), followed by
sofosbuvir/ledipasvir (20 out of 52, 38%). Seven patients
were treated with a sofosbuvir/simeprevir regimen with
ribavirin (5 of 7, 71%) for 12 weeks or without ribavirin
(1 of 7, 14%) for 24 weeks. One patient (1 of 7, 14%) was
treated with sofosbuvir/simeprevir for 12 weeks without
ribavirin and still reached SVR. Three patients received so-
fosbuvir/daclatasvir with (1 out of 3, 33%) or without rib-
avirin (2 out of 3, 67%) for 24 weeks. The remaining 9%
(5 out of 57, 9%) were treated with paritaprevir/ritonavir/
ombitasvir and ribavirin for 12 weeks.
Of all HCV genotypes, patients with genotype 4 had the
largest number of relapses (8 out of 57; 14%). Of all geno-
type 4 patients 56% (32 out of 57) were treatment-experi-
enced and 53% (30 out of 57) were cirrhotic. Genotype 4
without SVR were treatment-experienced in 63% (5 of 8)
and cirrhotic in 63% (5 of 8) of cases. Most relapses oc-
curred in the group that received sofosbuvir/ribavirin for
24 weeks, with 5 (5 out of 22, 23%) patients relapsing and
one (1 out of 22, 5%) showing a breakthrough during ther-
apy. In contrast, all patients that received sofosbuvir/ledi-
pasvir (± ribavirin for 12 or 24 weeks) (20 of 20, 100%)
and all three that received sofosbuvir/daclatasvir (± rib-
avirin for 24 weeks) reached SVR. Of 5 patients who re-
ceived paritaprevir/ritonavir/ombitasvir with ribavirin for
12 weeks, 4 patients achieved SVR (4 out of 5, 80%) with
1 breakthrough.
Overall, 53 patients received their DAA treatment in com-
bination with PEG-IFN. Sixteen patients (16 out of 167;
10%) with genotype 1a received a sofosbuvir/ribavirin
therapy with PEG-IFN for 12 weeks (15 out of 16) or 24
weeks (1 out of 16). All of them reached SVR. In the geno-
type 1b group only 11 patients (11 out of 175; 6%) received
a sofosbuvir/ribavirin/PEG-IFN combination for 12 weeks.
Two of them did not reach SVR (2 out of 11). Of all geno-
types, genotype 3 had the largest number of patients treated
with PEG-IFN (20 out of 107; 19%). Ten patients received
a sofosbuvir/ribavirin/PEG-IFN combination for 12 or 24
weeks, and 10 received a sofosbuvir/daclatasvir/PEG-IFN
combination with or without ribavirin. Two (10%) of the
genotype 3 patients that received DAA plus PEG-IFN did
not achieve SVR. Six patients in the genotype 4 group
also received a combination with sofosbuvir/ribavirin and
PEG-IFN for 12 weeks (6 of 57; 11%) and they all reached
SVR.
As shown in figure 2, 35 patients in total did not achieve an
SVR (32 relapses, 3 breakthroughs). If a relapse occurred,
it usually became apparent within the first four weeks of
the end of treatment. Later relapses were only seen in 3
out of 35 cases. Patients who did relapse had advanced fi-
brosis in 89% (31 out of 35) versus 68% in the group of
patients that did achieve SVR (358 out of 530). Of all 35
patients who experienced treatment failure, 17 were treat-
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ment-naïve (49%). Of all 530 patients who reached SVR,
293 were treatment naïve (293 out of 530, 55%).
Resistance-associated substitutions (RAS) were analysed
in 14 out of 35 (40%) treatment failure patients. The most
frequent RAS occurred in the NS5A gene (9 out of 14;
60%). This is in concordance with international studies on
RAS incidence [13–15]
Re-treatment of this group was successful in a large pro-
portion of patients (fig. 3). Of 16 patients that did receive
re-treatment, 14 patients achieved SVR (88%). For several
patients, reimbursement of re-treatment is currently under
revision. Only one patient did not have any further treat-
ment options based on his RAS profile.
Discussion
This Swiss data for novel DAA treatment of CHC shows
SVR rates very similar to those from the registration trials
[1–3, 16]. This is in accordance with other studies that
also reproduce the generally excellent SVR rates, especial-
ly among patients with genotype 1 CHC [17–19]. For the
observed time period between 2014 and mid-2016, geno-
types 2 and especially 4 had limited treatment options. The
data reported here do not take into account the introduc-
tion of novel DAAs such as elbasvir/grazoprevir (April
2016) and sofosbuvir/velpatasvir (January 2017) that were
licensed after this study and should significantly improve
the SVR rates in these patient groups [20, 21]
Most relapses were detected early in the post-treatment pe-
riod, usually within the first 4 weeks. Fortunately, re-treat-
ment was successful in most patients.
Access to DAA treatment and reimbursement of the very
high therapy costs is a worldwide challenge for HCV pa-
tients as well as for healthcare systems [22–25]. Limita-
tions of access and reimbursement have been introduced
in many countries [26]. Beginning in 2014, the reimburse-
ment of DAA therapies in Switzerland was limited to pa-
tients that had histologically verified advanced fibrosis or
cirrhosis (Metavir F3 or F4) or showed transient elastog-
raphy values >9.5 kPa in two consecutive measurements
with a minimum interval of 3 months [27]. Moreover, sev-
eral of the recommended therapeutics were not approved
or reimbursed. This made modifications and deviations
from the treatment recommendations by EASL necessary
in 2014 and early 2015. Thirty percent of patients that
did suffer a relapse were not treated according to interna-
tional guidelines due to limitations of availability or reim-
bursement. Until the market introduction of paritaprevir/ri-
tonavir/ombitasvir plus ribavirin, and grazoprevir/elbasvir
in mid-2016, there was no approved interferon-free treat-
ment regimen for HCV genotype 4 available in Switzer-
land, and alternative treatments required case-by-case ap-
proval of reimbursement by health insurance providers.
Since the analysis of our data, several pan-genotypic treat-
ments have been approved that show high efficacy and
SVR rates. Moreover, limitation for treatment reimburse-
ment according to fibrosis grade has been lifted mean-
Figure 3: Treatment and re-treatment of relapsing patients and clinically relevant RAS.DCV = daclatasvir; DSV = dasabuvir; ETR = end-of-
treatment response; GT = genotype; HIV = human immunodeficiency virus; LDV = ledipasvir; n.a. = test results not available or no RAS test
was performed; n/t = not taken (patient did not take RBV); PAR = paritaprevir; OMB = ombitasvir; PEG-INF = pegylated interferon; RAS = re-
sistance associated substitutions; RBV = ribavirin; SMV = simeprevir; SOF = sofosbuvir; SVR = sustained virological response; SVR12 = neg-
ative HCV-PCR 12 weeks after end of treatment; SVR24 = negative HCV-PCR 12 weeks after end of treatment.* No RAS detected.
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while. These new circumstances expand the population of
HCV patients that will be treated. Future studies will need
to include data on these new patient populations and med-
ications.
This study highlights the importance of the early adoption
of internationally accepted treatment guidelines, if possi-
ble. Moreover, approved but suboptimal treatment regi-
mens that did comply with national drug availability and
reimbursement limitations may have generated excessive
costs for the healthcare system.
Our study has limitations. Patients were only included
from three referral centres in this non-randomised obser-
vational study with a retro- and prospective follow-up.
Therefore, the study population might not reflect the stan-
dard Swiss HCV population. But at the same time, patients
with advanced fibrosis and cirrhosis might be overrepre-
sented in this tertiary care population. As we have shown,
the SVR rate in this population is lower, and therefore
these excellent SVR results might nevertheless be repre-
sentative for Switzerland. Finally, the median follow-up
period is relatively short, but it is well documented that late
relapses are extremely uncommon [28]. Accordingly, this
short follow-up has no relevant impact on the SVR report-
ed in this study
In summary, data from Switzerland for DAA treatment in
CHC confirm the excellent efficacy of these drugs. These
results are novel and have not been reported for Switzer-
land so far. They are in line with other national and in-
ternational studies reporting excellent overall outcomes for
DAA in a post-approval real-life setting. Patients who do
suffer a relapse can in most cases be successfully re-treat-
ed. Limitations of access prevented optimal therapy in
some patients.
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Appendix 1
Supplementary data
Explanation of supplementary figures
Patients with relapse or breakthrough are marked in or-
ange. Patients marked in yellow received PEG-IFN in ad-
dition to their DAA therapy. The number of patients re-
ceiving PEG-IFN is marked with *.
16 patients with genotype 1a and 11 patients with genotype
1b were treated with DAA plus PEG-IFN. None of the pa-
tients with genotype 2 were treated with additional PEG-
IFN. Twenty patients with genotype 3 and 6 patients with
genotype 4 were treated with DAA plus PEG-IFN. Eight
patients with HCV genotype 1 were excluded from analy-
sis becaue of lack of HCV subtyping.
NON = no second DAA; n/t = not taken (patient did not
take RBV); GT = genotype; BT = breakthrough; DCV
= daclatasvir; DSV = dasabuvir; GT = genotype; LDV
= ledipasvir; PTV/r/OBV = paritaprevir/ritonavir/om-
bitasvir; RBV = ribavirin; SMV = simeprevir; SOF = so-
fosbuvir; PEG-IFN = pegylated interferon.
Supplementary figures
Figure S1a: Patients with genotype 1a.
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Figure S1b: Patients with genotype 1b.
Figure S2: Patients with genotype 2.
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Figure S3: Patients with genotype 3.
Figure S4: Patients with genotype 4.
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